Roivant spinout Priovant and its backers—including Pfizer—reported Phase 2 results showing brepocitinib achieved statistically and clinically meaningful improvements in cutaneous sarcoidosis, outperforming placebo in a small randomized study. Investigators described the topline as notably strong for a rare dermatologic indication. The data strengthen brepocitinib’s position across several immune‑mediated skin diseases and may accelerate regulatory and commercial planning for larger trials. Sponsors will need to confirm safety and efficacy in broader cohorts, but the midstage readout improves the candidate’s near‑term valuation and partnership prospects.